NCT05253053View on ClinicalTrials.gov

To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

April 13, 2022

Primary Completion Date

August 31, 2024

Study Completion Date

August 31, 2024

Conditions
Advanced Solid TumorCholangiocarcinomaBiliary Tract CancerHER2-negative Breast CancerTriple Negative Breast CancerSmall-cell Lung CancerBladder CancerProstate CancerThyroid CancerGastric CancerGallbladder Cancer
Interventions
DRUG

TT-00420

TT-00420 tablet will be administered orally once daily per protocol defined schedule.

DRUG

Combination Product: Atezolizumab

Atezolizumab would be administered via infusion on Day 1 of 21-day cycle

DRUG

Combination Product: Nab-Paclitaxel

Nab-Paclitaxel would be administered via infusion on Day 1 and 8 of 21-day cycle

Trial Locations (9)

Unknown

The First Affiliated Hospital of Wannan Medical College, Wuhu

Henan Cancer Hospital, Zhengzhou

Hunan Cancer Hospital, Changsha

Nanjing Drum Tower Hospital, Nanjing

Jilin Cancer Hospital, Changchun

Shandong Cancer Hospital, Jinan

Beijing Cancer Hospital, Beijing

Peking University Third Hospital, Beijing

Fudan Univisity Shanghai Cancer Center, Shanghai

All Listed Sponsors
lead

TransThera Sciences (Nanjing), Inc.

INDUSTRY